Forensic Analysis · Pharmaceuticals & Biotechnology · as of Nov 9, 2026
AbbVie Inc. (ABBV)
A forensic read on AbbVie Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
B · Sound & dependable
Forensic grade
Clean
Earnings quality
1
Forensic signals
8.6%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (auditor quality, say on pay, board independence, going concern). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
AbbVie Inc. earns a B (Sound & dependable) forensic quality grade. 1 forensic signal was flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
11.0%
FY2025
Return on invested capital.Return on invested capital is 11.0% in the latest fiscal year, against 11.8% in FY2023, having run between 9.4% and 11.8% across FY2023–FY2025 with no direction held. After-tax operating profit was $9.9B in FY2023 and $9.8B in FY2025, with operating income at 23.5% of revenue in FY2023, 16.2% in FY2024 and 24.6% in FY2025. The capital base behind it went from $84.1B in FY2023 to $89.4B in FY2025 (+6%), while the revenue it carried went from $54.3B to $61.2B. Across FY2024–FY2025, $19.9B went into capital expenditure and acquisitions against $1.5B of depreciation. The base is struck net of amortisation, write-downs and the current liabilities that fund it, so it moved by less than that spending net of the wear, and this row does not say which of those absorbed the difference. FY2023's operating profit carried a $4.2B asset write-down that alone took about 3.9 points off that year's return, so the FY2025 return is being compared with a base year that charge had already pulled down. FY2024's operating profit carried a $4.5B asset write-down that alone took about 4.6 points off that year's return; FY2024 sits between the two ends of FY2023–FY2025, so the charge shapes the path between them without moving the change across it. A non-cash write-down lowers the reported return in the year it lands.
Key fundamentals
Latest Revenue$61.16B
Revenue Growth YoY+8.6%
Revenue CAGR (2yr)+6.1%
Net Margin6.9%
Free Cash Flow$17.82B
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from AbbVie Inc.'s actual 10-K/10-Q/8-K filings?